Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 10:02 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 985–1008 of 1,265 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Pre-Screening Clear all

Conditions: Bacterial Infections
Interventions: XNW4107, Imipenem/Cilastatin; Drug
Lead sponsor: Evopoint Biosciences Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 2
States / cities: Miami, Florida • Orlando, Florida

Conditions: Aneuploidy, Birth Defect
Interventions: video; Other
Lead sponsor: University of South Florida; Other
Eligibility: 18 Years and older · Female only
Enrollment: 106 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Insulin Resistance, Hyperinsulinemia, Metabolic Dysfunction Associated Steatotic Liver Disease, Non-Alcoholic Fatty Liver Disease, Prediabetic State, Obesity
Interventions: Insulin human, Octreotide Acetate, Glucagon, Growth Hormone, Human, 20% D-glucose (aq), [6,6-2H2] D-glucose, [1-13C1] sodium acetate, Nestle BOOST Plus, KIND Bar, Harvard Apparatus PHD ULTRA CP syringe pump, Yellow Springs Instruments (YSI) 2500 Biochemistry Glucose/Lactate Analyzer; Drug · Diagnostic Test · Dietary Supplement + 1 more
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2029
U.S. locations: 1
States / cities: New York, New York

Conditions: Heart Valve Disease, TAVI, M-TEER, TTVI, TMVI, T-TEER, Mitraclip, TriClip
Interventions: Medical imaging analysis via artificial intelligence algorithms; Diagnostic Test
Lead sponsor: Montreal Heart Institute; Other
Eligibility: 18 Years and older
Enrollment: 21,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: New York, New York

Conditions: Surgical Site Infection
Interventions: Mupirocin, Chlorhexidine gluconate, Cefazolin, Vancomycin, Nasal Povidone Iodine; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 23,005 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 11
States / cities: Miami, Florida • Iowa City, Iowa • Baltimore, Maryland + 8 more

Conditions: Plasma Cell Disorder
Interventions: 75gm HDAA, 100gm HDAA, 125gm HDAA; Drug
Lead sponsor: University of Arkansas; Other
Eligibility: 18 Years to 100 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Cancer
Interventions: Online educational video; Other
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 260 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Locally Advanced Cutaneous Melanoma, Locally Advanced Mucosal Melanoma, Metastatic Acral Melanoma, Metastatic Conjunctival Melanoma, Metastatic Cutaneous Melanoma, Metastatic HER2-Negative Breast Carcinoma, Metastatic Hormone Receptor-Positive Breast Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Mucosal Melanoma, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8, Recurrent Cutaneous Melanoma, Recurrent HER2-Negative Breast Carcinoma, Recurrent Hormone Receptor-Positive Breast Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Recurrent Mucosal Melanoma, Stage III Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Unresectable Acral Melanoma, Unresectable Cutaneous Melanoma, Unresectable Lung Non-Small Cell Carcinoma, Unresectable Mucosal Melanoma
Interventions: Neoantigen Peptide Vaccine, Nivolumab, Poly ICLC, Echocardiography Test, Multigated Acquisition Scan, Biopsy Procedure, Biospecimen Collection, Computed Tomography, Positron Emission Tomography, Ruxolitinib; Biological · Drug · Procedure
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: PTSD
Interventions: Day 1 Assessments, Day 2 Fear Learning, Day 3 Fear Extinction, Moderate Intensity Exercise, Low Intensity Exercise, Day 4 Recall of Fear Extinction; Other · Behavioral
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 21 Years to 50 Years · Female only
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Lung Cancer - Non Small Cell
Interventions: EXERCISE TRAINING WITH OR WITHOUT MEDICATION; Behavioral
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Stage I - II Primary Lung Cancer, Stage I Lung Cancer, Stage II Lung Cancer, Lung Cancer Stage I, Lung Cancer Stage II, Lung Cancer
Interventions: AveCure 16 Gauge Flexible Microwave Ablation Probe; Device
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 22 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Intellectual Disability, Developmental Disability, Axis I Diagnosis, Mental Illness, Covid19, Coronavirus
Interventions: Generic Best Practices, Tailored Best Practices; Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 415 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Speech
Interventions: MEG/EEG, MRI, Speaking Tasks; Behavioral
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 2
States / cities: Madison, Wisconsin • Milwaukee, Wisconsin

Conditions: Substance Abuse
Interventions: Meetings with implementation leader(s), the SAAS survey, Patient surveys; Behavioral
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 113,123 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 2
States / cities: Boston, Massachusetts • New York, New York

Conditions: Myeloablative Allogeneic Hematopoietic Cell Transplantation, Intraoral Photobiomodulation Therapy, Oral Mucositis, Mucosal Ulcer
Interventions: THOR LX2.3 with LED Lollipop; Device
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Major Depressive Disorder
Interventions: Ketamine, Psychotherapy; Drug · Behavioral
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years to 90 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Alcohol Drinking
Interventions: Enhanced Usual Care (pre-operative), Preoperative Virtual Health Coaching, Usual surgical care (post-operative), Postoperative Virtual Health Coaching, On-Track (Post-operative); Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: 21 Years to 75 Years
Enrollment: 440 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Pain Management, Pain, Intractable, Pain, Chronic Disease
Interventions: Spinal cord stimulation (SCS); Other
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 85 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Non-small Cell Lung Cancer, Colorectal Cancer, Triple Negative Breast Cancer, Pancreas Cancer
Interventions: Immunotherapy, Chemotherapy, CRC surgical resection, Colonoscopy; Drug · Procedure
Lead sponsor: Persephone Biosciences; Industry
Eligibility: 18 Years and older
Enrollment: 5,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2028
U.S. locations: 10
States / cities: Orange, California • San Diego, California • Miami, Florida + 6 more

Conditions: Recurrent B Acute Lymphoblastic Leukemia, Recurrent B-Cell Non-Hodgkin Lymphoma, Refractory B Acute Lymphoblastic Leukemia, Refractory B-Cell Non-Hodgkin Lymphoma, Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma
Interventions: Interferon Beta-1A, X-Ray Imaging, Echocardiography, Multigated Acquisition Scan, Computed Tomography, Positron Emission Tomography, Lumbar Puncture, Bone Marrow Aspiration, Bone Marrow Biopsy, Biospecimen Collection, Biopsy; Biological · Procedure
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Obesity & Overweight
Interventions: Standard Medical Care with an Obesity Management Medication, Cardiovascular Exercise Training, Resistance Exercise Training, Nutrition Counseling; Other · Behavioral
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 18 Years to 64 Years
Enrollment: 198 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Orthopedic Trauma, Sleep Quality
Interventions: Standard Postoperative Care, Zolpidem, Melatonin, Sleep Hygiene Education, Actigraph GT3X-BT Actigraph; Other · Drug · Dietary Supplement + 2 more
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Attention Deficit Hyperactivity Disorder
Interventions: OPDC-34712, Placebo, Stimulant Therapy; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 740 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 35
States / cities: Little Rock, Arkansas • Beverly Hills, California • Irvine, California + 32 more

Conditions: Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm, Triple-Negative Breast Carcinoma, Unresectable Malignant Solid Neoplasm
Interventions: BET Bromodomain Inhibitor ZEN-3694, Binimetinib, Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging; Drug · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 4
States / cities: Boston, Massachusetts • Galveston, Texas • Houston, Texas

Search by objective public record fields.

Pharmacokinetics of XNW4107 in Subjects With Various Degrees of Renal Function

Use of Videos to Improve Patient Knowledge on Prenatal Genetics

Human Models of Selective Insulin Resistance: Pancreatic Clamp

Enhanced Valves Interventions and Safe AI Generated End Results

Checklist to Prevent MRSA Surgical Site Infections

High Dose Ascorbic Acid (HDAA) in Patients With Plasma Cell Disorders

Education About Health and Cancer Study

Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer

Exercise and Therapeutic Learning Among Women With PTSD

The Impact of Exercise on the Tumor Microenvironment in Patients With Lung Cancer

Avecure Flexible Microwave Ablation Probe For Lung Nodules

Best Practices to Prevent COVID-19 Illness in Staff and People With Serious Mental Illness and Developmental Disabilities in Congregate Living Settings

Behavioral and Neural Responses to External Alterations of Speech Variability

A Phased-Implementation Feasibility and Proof-of-Concept Study to Assess Incorporating the NIDA CTN Common Data Elements (CDEs) Into the Electronic Health Record (EHR) in Large Primary Care Settings ("CDE-EHR-PC" Study), Phase 3

Intraoral Photobiomodulation Therapy to Prevent Oral Mucositis in Patients Undergoing Hematopoietic Cell Transplantation

Ketamine-Assisted Psychotherapy (KAP) Compared to Ketamine Alone for the Treatment of Depression

Alcohol Screening and Preoperative Intervention Research Study - 2

Sensory Spinal Cord Stimulation

ARGONAUT: Stool and Blood Sample Bank for Cancer Patients

Interferon-Beta-1a (FP-1201) to Prevent Toxicities After CD19-Directed CAR T-Cell Therapy

Changes in Body Composition Including Muscle With Anti-Obesity Medications, Both With and Without Exercise

Sleep Quality and the Efficacy of a Multimodal Sleep Pathway in Hospitalized Orthopedic Trauma Patients

Study of the Safety and Efficacy of OPC-34712 as a Complementary Therapy in the Treatment of Adult Attention Deficit/Hyperactivity Disorder

Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer